<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05122234</url>
  </required_header>
  <id_info>
    <org_study_id>54/FI/P-KCOVID-19.2B3/IX/2020</org_study_id>
    <nct_id>NCT05122234</nct_id>
  </id_info>
  <brief_title>Mesenchymal Stem Cell Secretome In Severe Cases of COVID-19</brief_title>
  <official_title>Effectiveness and Safety Profile of Mesenchymal Stem Cell Secretomes as a Treatment for Severe Cases of COVID-19</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Indonesia University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Indonesia University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a multi-centre randomized controlled trial involving severe covid-19 patients.&#xD;
      The intervention group will receive mesenchymal stem cell secretomes and standard covid-19&#xD;
      therapy, while the control group receive placebo and standard covid-19 therapy. Clinical&#xD;
      presentation, inflamatory marker, laboratory and radiological parameters, RT-PCR conversion,&#xD;
      safety profile, and mortality rate will be monitored for a maximum of 14 days after&#xD;
      intervention.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 10, 2020</start_date>
  <completion_date type="Actual">November 14, 2021</completion_date>
  <primary_completion_date type="Actual">July 30, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assessment of inflamation marker levels</measure>
    <time_frame>Day 0 (before intervention), day 7, day 14</time_frame>
    <description>The inflamatory marker assessed in this study is IL-6, IL-10, LIF, VEGF, and Ferritin. The inflamatory marker level will assess on day 0 (before intervention), day 7 after intervention, and day 14 after intervention.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assessment of clinical outcome</measure>
    <time_frame>before and after intervention (maximum 14 days after intervention)</time_frame>
    <description>Clinical outcome assessed in this study were body temperature, oxygen saturation, respiratory rate, shortness of breath, cough, and phlegm on cough.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of laboratory routine</measure>
    <time_frame>before and after intervention (maximum 14 days after intervention)</time_frame>
    <description>Laboratory routine assessed in this study is NLR, lymphocyte count, thrombocytes count, CRP, blood gas analysis, bilirubin, albumin, SGOT, SGPT, ureum/creatinin, glomerular filtration rate (GFR), electrolyte, myoglobin, troponin, D-dimer.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of photo thorax</measure>
    <time_frame>before and after intervention (maximum 14 days after intervention)</time_frame>
    <description>Photo thorax will assess before and after intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of RT-PCR conversion</measure>
    <time_frame>before and after intervention (maximum 14 days after intervention)</time_frame>
    <description>RT-PCR conversion will assess before and after intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality rate</measure>
    <time_frame>maximum 14 days after intervention</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>COVID-19</condition>
  <arm_group>
    <arm_group_label>Secretome - mesenchymal stem cell group (n = 20)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This group will be given secretome - mesenchymal stem cell and COVID-19 standard therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control ( n= 20)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>This group will be given placebo and COVID-19 standard therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Injection of secretome - mesenchymal stem cell</intervention_name>
    <description>Secretome will be given once at a dose of 15 ml per administration dissolved in 100 ml of normal saline. The administration is done intravenously for 60 minutes.</description>
    <arm_group_label>Secretome - mesenchymal stem cell group (n = 20)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Normal saline</description>
    <arm_group_label>Control ( n= 20)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Standard treatment of Covid-19</intervention_name>
    <description>Standard treatment of Covid-19 based on national protocol.</description>
    <arm_group_label>Control ( n= 20)</arm_group_label>
    <arm_group_label>Secretome - mesenchymal stem cell group (n = 20)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. All individuals aged 18 to 65 years&#xD;
&#xD;
          2. It has been confirmed positive for COVID-19 by throat swab / sputum / brochoalveolar&#xD;
             lavage (BAL) with real-time reverse transcription polymerase chain reaction (RT-PCR)&#xD;
&#xD;
          3. Categorized as a severe case of COVID-19 patient&#xD;
&#xD;
          4. Agree to participate and sign the informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History of allergy to penicillin, streptomycin, and amphotericin-B&#xD;
&#xD;
          2. Have any cancer conditions&#xD;
&#xD;
          3. Active in other intervention studies&#xD;
&#xD;
          4. Have had other intervention studies in the last 3 months&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Murdani Abdullah, Prof. M.D., PhD, FACG, FASGE</last_name>
    <role>Principal Investigator</role>
    <affiliation>Departemen of Internal Medicine, Faculty of Medicine, University of Indonesia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>RSUPN Dr. Cipto Mangunkusumo</name>
      <address>
        <city>Jakarta Pusat</city>
        <state>DKI Jakarta</state>
        <country>Indonesia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>RSUP Fatmawati</name>
      <address>
        <city>Jakarta</city>
        <state>DKI Jakarta</state>
        <country>Indonesia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>RSUP Persahabatan</name>
      <address>
        <city>Jakarta</city>
        <state>DKI Jakarta</state>
        <country>Indonesia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rumah Sakit Universitas Indonesia</name>
      <address>
        <city>Depok</city>
        <state>Jawa Barat</state>
        <country>Indonesia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Indonesia</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 13, 2021</study_first_submitted>
  <study_first_submitted_qc>November 13, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 16, 2021</study_first_posted>
  <last_update_submitted>November 13, 2021</last_update_submitted>
  <last_update_submitted_qc>November 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Indonesia University</investigator_affiliation>
    <investigator_full_name>Murdani abdullah</investigator_full_name>
    <investigator_title>Prof. M.D., PhD, FACG, FASGE</investigator_title>
  </responsible_party>
  <keyword>Severe Covid-19</keyword>
  <keyword>secretome</keyword>
  <keyword>mesenchymal stem cell</keyword>
  <keyword>cytokine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

